Skip to main content
Top
Published in: Breast Cancer Research 6/2006

Open Access 01-12-2006 | Research article

Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy

Authors: Eugenio Paci, Guido Miccinesi, Donella Puliti, Paola Baldazzi, Vincenzo De Lisi, Fabio Falcini, Claudia Cirilli, Stefano Ferretti, Lucia Mangone, Alba Carola Finarelli, Stefano Rosso, Nereo Segnan, Fabrizio Stracci, Adele Traina, Rosario Tumino, Manuel Zorzi

Published in: Breast Cancer Research | Issue 6/2006

Login to get access

Abstract

Introduction

Excess of incidence rates is the expected consequence of service screening. The aim of this paper is to estimate the quota attributable to overdiagnosis in the breast cancer screening programmes in Northern and Central Italy.

Methods

All patients with breast cancer diagnosed between 50 and 74 years who were resident in screening areas in the six years before and five years after the start of the screening programme were included. We calculated a corrected-for-lead-time number of observed cases for each calendar year. The number of observed incident cases was reduced by the number of screen-detected cases in that year and incremented by the estimated number of screen-detected cases that would have arisen clinically in that year.

Results

In total we included 13,519 and 13,999 breast cancer cases diagnosed in the pre-screening and screening years, respectively. In total, the excess ratio of observed to predicted in situ and invasive cases was 36.2%. After correction for lead time the excess ratio was 4.6% (95% confidence interval 2 to 7%) and for invasive cases only it was 3.2% (95% confidence interval 1 to 6%).

Conclusion

The remaining excess of cancers after individual correction for lead time was lower than 5%.
Appendix
Available only for authorised users
Literature
2.
go back to reference The National Centre for Screening Monitoring: 4th Report. Epidemiol Prev. 2006, 30 (Suppl 3): 7-16. The National Centre for Screening Monitoring: 4th Report. Epidemiol Prev. 2006, 30 (Suppl 3): 7-16.
3.
go back to reference Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L, Puthar E, eds: European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. 2006, Luxembourg: Office for Official Publications of the European Commission, 4 Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L, Puthar E, eds: European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. 2006, Luxembourg: Office for Official Publications of the European Commission, 4
4.
go back to reference Morrison A: Screening in Chronic Disease. 1992, New York: Oxford University Press, 2 Morrison A: Screening in Chronic Disease. 1992, New York: Oxford University Press, 2
6.
go back to reference AIRT Working Group: Italian Cancer Figures – Report 2006. Incidence, mortality and estimates. Epidemiol Prev. 2006, 30 (Suppl 2): 12-16. AIRT Working Group: Italian Cancer Figures – Report 2006. Incidence, mortality and estimates. Epidemiol Prev. 2006, 30 (Suppl 2): 12-16.
7.
go back to reference Walter SD, Day NE: Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol. 1983, 118: 865-886.PubMed Walter SD, Day NE: Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol. 1983, 118: 865-886.PubMed
8.
go back to reference Paci E, Warwick J, Falini P, Duffy SW: Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern?. J Med Screen. 2004, 11: 23-27. 10.1258/096914104772950718.PubMed Paci E, Warwick J, Falini P, Duffy SW: Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern?. J Med Screen. 2004, 11: 23-27. 10.1258/096914104772950718.PubMed
9.
go back to reference Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002, 94: 981-990.CrossRefPubMed Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002, 94: 981-990.CrossRefPubMed
10.
go back to reference Paci E, Duffy SW, Giorgi D, Prevost TC, Rosselli del Turco M: Population-based breast cancer screening programmes: estimates of sensitivity, overdiagnosis and early prediction of the benefit. Quantitative Methods for the Evaluation of Cancer Screening. Edited by: Duffy SW, Hill C, Esteve J. 2001, London: Arnold, 127-135. Paci E, Duffy SW, Giorgi D, Prevost TC, Rosselli del Turco M: Population-based breast cancer screening programmes: estimates of sensitivity, overdiagnosis and early prediction of the benefit. Quantitative Methods for the Evaluation of Cancer Screening. Edited by: Duffy SW, Hill C, Esteve J. 2001, London: Arnold, 127-135.
11.
go back to reference McCann J, Treasure P, Duffy S: Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. J Med Screen. 2004, 11: 117-125. 10.1258/0969141041732201.CrossRefPubMed McCann J, Treasure P, Duffy S: Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. J Med Screen. 2004, 11: 117-125. 10.1258/0969141041732201.CrossRefPubMed
12.
go back to reference Moss S: Overdiagnosis and over-treatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res. 2005, 7: 230-234. 10.1186/bcr1314.CrossRefPubMedPubMedCentral Moss S: Overdiagnosis and over-treatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res. 2005, 7: 230-234. 10.1186/bcr1314.CrossRefPubMedPubMedCentral
13.
go back to reference Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP: Rate of overdiagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ. 2006, 332: 689-692. 10.1136/bmj.38764.572569.7C.CrossRefPubMedPubMedCentral Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP: Rate of overdiagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ. 2006, 332: 689-692. 10.1136/bmj.38764.572569.7C.CrossRefPubMedPubMedCentral
14.
go back to reference Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Björneld L, Myles JP, Warwick J: Overdiagnosis and over-treatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005, 7: 258-265. 10.1186/bcr1354.CrossRefPubMedPubMedCentral Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Björneld L, Myles JP, Warwick J: Overdiagnosis and over-treatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005, 7: 258-265. 10.1186/bcr1354.CrossRefPubMedPubMedCentral
15.
go back to reference Weedon-Fekjaer H, Vatten LJ, Aalen OO, Lindqvist B, Tretli S: Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results. J Med Screen. 2005, 12: 172-178. 10.1258/096914105775220732.CrossRefPubMed Weedon-Fekjaer H, Vatten LJ, Aalen OO, Lindqvist B, Tretli S: Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results. J Med Screen. 2005, 12: 172-178. 10.1258/096914105775220732.CrossRefPubMed
16.
go back to reference Moller B, Weedon-Fekjaer H, Hakulinen T, Tryggvadottir L, Storm HH, Talback M, Haldorsen T: The influence of mammographic screening on national trends in breast cancer incidence. Eur J Cancer Prev. 2005, 14: 117-128. 10.1097/00008469-200504000-00007.CrossRefPubMed Moller B, Weedon-Fekjaer H, Hakulinen T, Tryggvadottir L, Storm HH, Talback M, Haldorsen T: The influence of mammographic screening on national trends in breast cancer incidence. Eur J Cancer Prev. 2005, 14: 117-128. 10.1097/00008469-200504000-00007.CrossRefPubMed
17.
go back to reference Jonsson H, Johansson R, Lenner P: Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer. 2005, 117: 842-847. 10.1002/ijc.21228.CrossRefPubMed Jonsson H, Johansson R, Lenner P: Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer. 2005, 117: 842-847. 10.1002/ijc.21228.CrossRefPubMed
Metadata
Title
Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy
Authors
Eugenio Paci
Guido Miccinesi
Donella Puliti
Paola Baldazzi
Vincenzo De Lisi
Fabio Falcini
Claudia Cirilli
Stefano Ferretti
Lucia Mangone
Alba Carola Finarelli
Stefano Rosso
Nereo Segnan
Fabrizio Stracci
Adele Traina
Rosario Tumino
Manuel Zorzi
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1625

Other articles of this Issue 6/2006

Breast Cancer Research 6/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine